Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000431904 | SCV000536639 | pathogenic | not provided | 2019-06-20 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 28544625, 29661262, 31435640) |
Labcorp Genetics |
RCV000699220 | SCV000827921 | pathogenic | Epilepsy, childhood absence, susceptibility to, 1; Epilepsy, childhood absence, susceptibility to, 5 | 2019-09-28 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed to be de novo in individuals affected with Dravet syndrome  (PMID: 28544625) and early onset treatable multifocal epilepsy with moderate intellectual disability (PMID: 28053010). ClinVar contains an entry for this variant (Variation ID: 393256). This variant is not present in population databases (ExAC no frequency). This sequence change replaces arginine with glutamine at codon 232 of the GABRB3 protein (p.Arg232Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. |
Diagnostic Laboratory, |
RCV001260891 | SCV001437991 | likely pathogenic | Intellectual disability | 2020-09-10 | criteria provided, single submitter | clinical testing |